ZOVOG TRIO 1

About

This medication represents a triple-combination therapy for the comprehensive management of type 2 diabetes mellitus, typically comprising Metformin, Glimepiride, and Pioglitazone. Metformin, a biguanide, reduces hepatic glucose production and enhances insulin sensitivity in peripheral tissues. Glimepiride, a sulfonylurea, stimulates insulin release from pancreatic beta cells. Pioglitazone, a thiazolidinedione, further improves insulin sensitivity in muscle, adipose tissue, and the liver. This synergistic action targets multiple pathophysiological defects inherent in type 2 diabetes, providing robust and potent glycemic control for adults whose blood sugar is inadequately managed by dual therapy or monotherapy. It aims to achieve optimal HbA1c levels, reduce insulin resistance, and mitigate the progression of diabetes-related complications by addressing various pathways of glucose dysregulation.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control.
• When dual therapy is insufficient.
• As an adjunct to diet and exercise.

Directions For Use

Take orally once daily with a meal to minimize gastrointestinal side effects. Follow your doctor's prescribed dosage and frequency carefully.

Benefits

• Comprehensive blood sugar control through multiple mechanisms.
• Significantly lowers HbA1c levels.
• Improves insulin sensitivity in various tissues.
• Stimulates endogenous insulin secretion.
• Convenient triple-drug combination.
• Helps prevent diabetes-related complications.

Side Effects

• Hypoglycemia
• Weight gain
• Edema/fluid retention
• Nausea
• Diarrhea
• Abdominal pain
• Headache
• Dizziness
• Lactic acidosis (rare, with metformin)
• Bone fractures (with pioglitazone)
• Bladder cancer (rare, with pioglitazone)
• Heart failure exacerbation (with pioglitazone)

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of hypoglycemia and lactic acidosis, especially with metformin.
• Pregnancy - Not recommended during pregnancy; insulin is generally the preferred treatment for diabetes in pregnant women.
• Breastfeeding - Avoid during breastfeeding as components may pass into breast milk and could potentially harm the infant.
• Liver - Contraindicated in severe hepatic impairment due to increased risk of lactic acidosis (metformin) and potential for liver toxicity (pioglitazone).
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to the risk of metformin accumulation and lactic acidosis.
• Lung - Use with caution in conditions causing hypoxia (e.g., severe respiratory failure) as it may increase the risk of lactic acidosis. Pioglitazone can also exacerbate fluid retention, which might impact lung function in susceptible individuals.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.